Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Quality of Life (QOL) in Patients with Advanced Hepatocellular Carcinoma (AHCC) in Clinical Trials and Health Technology Appraisal (HTA) Implications

Speaker(s)

Moon J1, Hurtado P1, Lucchino M2, Sathi C2, Vidalis A3, Demont E4, Gulotta G3, Dumoulin O3
1Alira Health, Cambridge, MA, USA, 2Alira Health, Paris, France, 3Alira Health, Basel, Switzerland, 4Alira Health, Barcelona, Spain

Background

HCC is the most common kind of liver cancer, accounting for 85% of cases, and it is the fourth leading cause of cancer mortality worldwide. Most patients are diagnosed at the advanced stage, which is associated with poor prognosis, negatively impacting QoL of patients and their willingness to comply with therapies. Inclusion of QoL metrics in clinical trials (CTs) is of particular importance for diseases with poor prognosis as they assess the intervention effect on patients’ functional status, psychological and social functioning, and wellbeing. This study aimed at understanding trends in the use of QoL metrics across CTs in aHCC and their role in HTA assessment across key European countries.

Methods

A focused comprehensive literature search was conducted using PubMed and Clinicaltrials.gov. A screening for pertinent articles was performed by reviewing titles and abstracts related to first- (1L) and second-line (2L) treatments in aHCC Phase II and III trials. Study selection and data extraction were independently performed by two researchers, based on relevance to aHCC and QoL metrics.

Results

The literature search identified 173 records of which 22 met inclusion criteria: 8 (9%) published papers and 14 (17%) on-going CTs. The study identified 2 HCC-specific, 2 cancer-specific and 2 generic QoL instruments. EORTC-QLQ-C30 and EORTC-QLQ-HCC18 were assessed in all published CT studies in 1L (n=6), whereas FACT-Hep and EQ-5D were used in 2L CT studies (n=2). EORTC-QLQ-C30 and EORTC-QLQ-HCC18 are the most used metrics in ongoing CTs (n=11). QoL instruments are accepted by HTA if appropriately included in CTs study design and method of controlling alpha inflation risk is considered important.

Conclusion

Despite the high relevance of QoL metrics in diseases with poor prognosis, such as aHCC, this study highlighted the limited use of QoL endpoints in aHCC clinical trials, not always reflecting HTA requirements in EU.

Code

PCR165

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

No Additional Disease & Conditions/Specialized Treatment Areas